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Cardiogenic shock develops in up to 10% of patients with acute myocardial infarction and continues to
have high mortality. Early invasive treatment is the default therapeutic approach in these patients. On
the basis of the results of the CULPRIT-SHOCK trial, culprit-only revascularization during the acute phase
is preferred over multivessel revascularization. Routine use of intra-aortic balloon pump (IABP) is not
recommended; however, the use of mechanical circulatory support has been increasing despite limited
observational data to support its use. Several studies support multivessel revascularization in patients
with uncomplicated ST-segment elevation acute myocardial infarction and simple nonculprit lesions to
improve subsequent clinical outcomes.
© 2019 Hellenic Society of Cardiology. Publishing services by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Recent studies have advanced our understanding and treatment
options for patients with cardiogenic shock in the setting of acute
coronary syndromes (ACS), as well as coronary revascularization in
ACS patients with multivessel disease.1e7 We provide an overview
of those studies and their anticipated impact on clinical practice.2. Cardiogenic shock in ACS patients
2.1. Medical vs. invasive treatment, complete vs. infarct-related
angioplasty
Cardiogenic shock is deﬁned as a state in which ineffective
cardiac output, caused by a primary cardiac disorder, results in both
clinical and biochemical manifestations of inadequate tissue
perfusion. Some patients with cardiogenic shock may not haveneapolis Heart Institute, 920
.: þ1 612 863 4204.
).
ty of Cardiology.
lishing services by Elsevier B.V. Thihypotension; however, a commonly used deﬁnition is persistent
hypotension (systolic blood pressure < 90 mmHg or mean blood
pressure 30 mmHg lower than the baseline value), elevated pul-
monary capillary wedge pressure (PCWP) (greater than 15 mmHg),
and depressed cardiac index (less than 1.8 L/min/m2 without sup-
port or less than 2.2 L/min/m2 with support) accompanied by signs
of hypoperfusion (such as reduced urine output, cold extremities,
and confusion).8 Cardiogenic shock develops in approximately 6-
10% of patients with ST-segment elevation myocardial infarction
(STEMI) and up to 3% of patients with non-ST-segment elevation
myocardial infarction (NSTEMI), with >50% mortality in both
settings.9e11 Common causes of cardiogenic shock include exten-
sive left ventricular injury, right ventricular infarction, mechanical
complications, or arrhythmias.
The ShouldWe Emergently Revascularize Occluded Coronaries for
Cardiogenic Shock (SHOCK) trial randomized 302 patients with
cardiogenic shock to early revascularization vs. initial medical stabi-
lization. Comparedwith themedical stabilization group, patientswho
had early revascularization had lower mortality, both after 6 months
(50.3% vs. 63.1%, respectively, RR 0.80 [95%CI 0.65e0.98], p¼ 0.027)12
and after 6 years (67.2% vs. 80.4%, p ¼ 0.028) of follow-up.13
Most (up to 80%) patients with cardiogenic shock in the setting
of ACS have multivessel coronary artery disease.14,15 Whethers is an open access article under the CC BY-NC-ND license (http://creativecommons.
Table 1
Guidelines for patients with cardiogenic shock due to myocardial infarction and multivessel coronary disease
Guidelines Recommendations Class Level of evidence
ACCF/AHA guidelines on STEMI
(2013)18
In patients with cardiogenic shock due to pump failure, PCI of a severe
stenosis in a large noninfarct artery might improve hemodynamic
stability and should be considered during the primary procedure.
Not speciﬁed Not speciﬁed
AHA/ACC guidelines on NSTEMI
(2014)19
Select a revascularization strategy based on the extent of CAD,
associated cardiac lesions, LV dysfunction, and prior revascularization.
I B
ESC/EACS on myocardial
revascularization (2018)22
In cardiogenic shock, routine revascularization of non-infarct-related
arteries (non-IRA) is not recommended during primary PCI.
III B
ACCF/AHA, American College of Cardiology Foundation/American Heart Association; STEMI, ST-segment elevation myocardial infarction; PCI, percutaneous coronary inter-
vention; NSTEMI, Non-ST-segment elevation myocardial infarction; CAD, coronary artery disease; LV, left ventricular; ESC/EACS, European Society of Cardiology/European
Association of Cardiothoracic Surgery.
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in those patients had been controversial. Hussain et al examined
210 patients with cardiogenic shock showing that complete revas-
cularization was independently associated with lower in-hospital
mortality.16 The 2017 European guidelines for STEMI favored com-
plete revascularization in patients with STEMI and cardiogenic
shock (class IIa, level of evidence C), while the 2013 ACCF/AHA
guidelines suggested that “shock or severe heart failure is perhaps
the only clinical scenario in which acute revascularization of sig-
niﬁcant stenoses in non-infarct arteries can be justiﬁed”.17,18 Simi-
larly, the 2014 AHA/ACCNSTEMI guidelines recommended selection
of a speciﬁc revascularization strategy on the basis of the degree,
severity, and extent of coronary artery disease, associated cardiac
lesions, extent of left ventricular dysfunction, and history of prior
revascularization (class I, level of evidence B)19 (Table 1 and Fig. 1).
The aforementioned question was deﬁnitely answered in the
Culprit Lesion-Only PCI Versus Multivessel Percutaneous Coronary
Intervention in Cardiogenic Shock (CULPRIT-SHOCK) trial. In this
multicenter, randomized controlled trial, 706 patients with either
STEMI or NSTEMI were randomized to culprit vessel-onlyFig. 1. Panel A: A patient with cardiogenic shock caused by non-ST-segment elevation m
complete obstruction of the left anterior descending artery (LAD) and an ulcerated lesion ca
present in the distal right coronary artery (RCA) causing 70% obstruction. Panel C: After the i
revealed. Panel D: Because of the proximal location of the LAD and CX lesions, it was decide
LAD. Two drug-eluting stents (DES) were implanted in the proximal CX. Panel E: One DES wa
restored in both vessels. PCI of the RCA was not performed.percutaneous coronary intervention (PCI) with possible staged
revascularization later versus immediate multivessel PCI. The inci-
dence of the composite primary endpoint of death or renal-
replacement therapy at 30 days was lower in patients who under-
went culprit lesion-only PCI (45.9% vs. 55.4%, RR 0.83 [95% CI 0.71-
0.96], p¼ 0.01). All-causemortality occurred in 149 (43.3%) patients
in the culprit lesion-only PCI group and in 176 (51.6%) in the mul-
tivessel PCI (RR 0.84 [95% CI 0.72-0.98], p ¼ 0.03) with a trend for a
lower need for renal replacement therapy (11.6% vs. 16.4%, respec-
tively, RR 0.71 [95% CI 0.49-1.03], p ¼ 0.07).2 Chronic total occlu-
sions (CTOs) are often present in patients with ACS and have been
associated with worse outcomes20,21 In the CULPRIT-SHOCK trial, at
least one CTO was present in 24% of patients in the multivessel PCI
group and in 22.4% of patients in the culprit-only PCI group. In
patients with at least one CTO, complete revascularization was
achieved in 81%. The subgroup analysis for the primary endpoint at
30 days showed better outcomes with culprit-only PCI (relative risk
0.67 [95% CI 0.46-0.97]) than with multivessel PCI.
On the basis of the CULPRIT-SHOCK trial, the 2018 European
Society of Cardiology/European Association of Cardiothoracicyocardial infarction underwent emergent coronary angiography, which demonstrated
using 90% obstruction, proximally, in the circumﬂex artery (CX). Panel B: A lesion was
nﬂation of a 2.5 mm balloon in the proximal LAD, severe diffuse disease in mid-LAD was
d to proceed with percutaneous coronary intervention (PCI) to the CX in addition to the
s implanted in the proximal LAD. Panel F: The ﬁnal result showed that TIMI ﬂow-3 was
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for the routine revascularization of non-infarct-related arteries
(non-IRA) during primary PCI in patients with STEMI and NSTEMI
complicated by cardiogenic shock.222.2. Mechanical circulatory support devices in cardiogenic shock
Intra-aortic balloon pump (IABP) has been the most commonly
used short-term mechanical circulatory support device because it is
easy to use, inexpensive, and readily available. IABP use declined
after the Intra-aortic Balloon Pump in Cardiogenic Shock II (IABP-
SHOCK II) trial. IABP-SHOCK II was the ﬁrst randomized controlled
trial that evaluated the use of the IABP in patients with acute MI
complicated by cardiogenic shock and showed similar 30-day (39.7%
vs. 41.3%, RR 0.96 [95% CI 0.79-1.17], p¼ 0.69) and 12-month (52% vs.
51%, RR 1.01 [95% CI 0.86-1.18], p ¼ 0.91) mortality. The trial was
criticized, however, because of the relatively small number of pa-
tients enrolled (n ¼ 600) and the lower than anticipated mortality
(40%) that reduced the power of the study. Moreover,10% of patients
crossed over from the control group to the IABP group.1 A recent
meta-analysis of seven trials that included a total of 790 patients
demonstrated no difference in 30-day mortality with vs. without
IABP in patients with acute MI and cardiogenic shock.23 Given the
IABP-SHOCK II trial results, the 2018 European guidelines on
myocardial revascularization recommend against the routine use of
IABP in patients with cardiogenic shock due to ACS (class III, level of
evidence B)18,22 (Table 2); however, the IABP can remain useful
particularly in patients in early stages of shock.
Veno-arterial extracorporeal membrane oxygenation (VA
ECMO) is often used in patients with cardiac arrest and cardiogenic
shock. A meta-analysis of 4 studies that included 235 patients with
cardiogenic shock after acute MI showed that VA ECMO was asso-
ciated with improved 30-day survival as compared with IABP (risk
difference 33%, [95% CI 14e52%], p ¼ 0.0008, NNT 3). When VA
ECMO was compared with Impella or Tandem Heart, 30-day sur-
vival was similar (risk difference 3% [95% CI 21 to 14%],
p ¼ 0.70).24
Seyfarth et al performed a prospective, randomized study
comparing Impella LP 2.5 with IABP in 25 patients with cardiogenic
shock caused by acute MI. After 30 minutes of support, the cardiac
index was signiﬁcantly higher in the Impella group than in the IABP
group; however, the overall 30-daymortality was similar in the two
groups.25 In another prospective, randomized trial that included 42
patients, Burkhoff et al tested whether or not TandemHeart pro-
vided superior hemodynamic support compared with IABP in pa-
tients with cardiogenic shock (due to MI in 70%). TandemHeart
improved the hemodynamic parameters but did not improve 30-
day survival.26 A recent meta-analysis of 148 patients from four
randomized trials that investigated the efﬁcacy and safety of Tan-
demHeart and Impella vs. IABP demonstrated that LVADs signiﬁ-
cantly increased mean arterial blood pressure and decreased
arterial lactate and PCWC at the cost of a high rate of bleeding fromTable 2
Guidelines for the use of mechanical circulatory support devices in patients with myoca
Guidelines Recommendations
ACCF/AHA guidelines on STEMI
(2013)18
The use of intra-aortic balloon pump (IABP) c
cardiogenic shock after STEMI who do not qu
ACCF/AHA guidelines on STEMI
(2013)18
Alternative LV assist devices for circulatory su
refractory cardiogenic shock.
ESC/EACS on myocardial
revascularization (2018)22
Routine use of IABP in patients with cardioge
ACCF/AHA, American College of Cardiology Foundation/American Heart Association; STE
ropean Society of Cardiology/European Association of Cardiothoracic Surgery; ACS, acutevascular access sites comparedwith IABP.27 The Impella versus IABP
Reducesmortality in STEMI patients treatedwith primary PCI in the
Severe cardiogenic SHOCK (IMPRESS) trial randomized 48 patients
with STEMI and cardiogenic shock to either Impella CP or IABP. The
all-cause mortality at 30 days and 6 months was similar in the two
groups (46% vs. 50%, p ¼ 0.92 and 50% vs. 50%, p ¼ 0.92%), while
Impella CP was associated with moremajor bleeding events (8 vs. 2
patients).28
Despite the lack of data demonstrating survival beneﬁt with
mechanical circulatory support, in the United States, use of IABP has
been decreasing and use of VA ECMO, Impella, and TandemHeart
has been increasing.29e31
The 2013 ACCF/AHA STEMI guidelines recommend the use of
LVADs as an alternative to IABP for patients with refractory
cardiogenic shock (class IIb, level of evidence C).18 Because of the
lack of strong data, the European revascularization guidelines do
not provide recommendations for the use of LVADs in patients with
MI complicated by cardiogenic shock (Table 2).3. Multivessel disease in acute coronary syndromes
3.1. Multivessel disease in NSTEMI
Approximately 40-80% of NSTEMI patients have multivessel
disease, and up to 40% of patients have more than one culprit
lesion.32 Culprit lesion(s) determination and the optimal revascu-
larization strategy remain controversial.33e37 The Impact of
Different Treatment in Multivessel Non-ST-Elevation Myocardial
Infarction Patients: One Stage Versus Multistaged Percutaneous
Coronary Intervention (SMILE) trial randomized 584 patients with
multivessel disease and NSTEMI to complete 1-stage coronary
revascularization vs. multi-stage revascularization. The complete 1-
stage coronary revascularization group had lower incidence of the
composite endpoint of cardiac death, death, reinfarction, rehospi-
talization for unstable angina, repeat coronary revascularization
(target vessel revascularization), and stroke at 1 year (13.63% vs.
23.19%, HR: 0.549 [95% CI 0.363-0.828], p ¼ 0.004), driven by lower
incidence of target vessel revascularization.38 The 2014 AHA/ACC
NSTEMI guidelines suggest that a strategy of multivessel PCI, in
contrast to culprit lesion-only PCI, may be reasonable in patients
undergoing coronary revascularization as part of treatment for
NSTEMI (class IIb, level of evidence C).19 The 2018 ESC/EACTS
guidelines on myocardial revascularization state that revasculari-
zation strategy should be based on the clinical status, comorbid-
ities, and disease severity according to the principles for stable
coronary artery disease (class I, level of evidence B)22 (Table 3).3.2. Multivessel disease in STEMI
Approximately 50% of STEMI patients havemultivessel coronary
artery disease, which is associated with lower rates of successful
myocardial reperfusion and high rate of major adverse cardiac evetsrdial infarction complicated by cardiogenic shock
Class Level of
evidence
ounterpulsation can be useful for patients with
ickly stabilize with pharmacological therapy.
IIa B
pport may be considered in patients with IIb C
nic shock due to ACS is not recommended. III B
MI, ST-segment elevation myocardial infarction; LV, left ventricular; ESC/EACS, Eu-
coronary syndrome.
Table 3
Guidelines for patients with NSTEMI and multivessel coronary artery disease without cardiogenic shock
Guidelines Recommendations Class Level of
evidence
AHA/ACC guidelines on
NSTEMI (2014)19
A strategy of multivessel PCI, in contrast to culprit lesion-only PCI, may be reasonable in patients
undergoing coronary revascularization as part of treatment for NSTE-ACS.
IIb B
ESC/EACS on myocardial
revascularization
(2018)22
It is recommended to base the revascularization strategy (ad hoc culprit lesion PCI/multivessel PCI/
CABG) on the clinical status and comorbidities, as well as the disease severity [i.e., the distribution
and angiographic lesion characteristics (e.g., SYNTAX score)], according to the principles for SCAD.
I B
AHA/ACC, American Heart Association/American College of Cardiology; NSTEMI, Non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention;
NSTE-ACS, Non-ST-segment elevation acute coronary syndrome; ESC/EACS, European Society of Cardiology/European Association of Cardiothoracic Surgery; CABG, coronary
artery bypass surgery; SYNTAX, Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; SCAD, stable coronary artery disease.
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PCI of the non-IRA during the index procedure may adversely affect
prognosis: Cavender et al examined 28,936 patients from the Na-
tional Cardiovascular Data Registry and found that multivessel PCI
during primary PCI was associated with higher in-hospital mor-
tality rates (7.9% vs. 5.1%, p <0.01).41 Hannah et al showed in an
observational study of 3,521 patients that culprit lesion-only PCI
was associated with lower in-hospital mortality than multivessel
PCI during the index procedure (0.9% vs. 2.4%, p ¼ 0.04). Staged
revascularization with PCI at 60 days after primary PCI, however,
reduced the one-year mortality compared with IRA-only PCI (1.3%
vs. 3.3%, p ¼ 0.04).42 A meta-analysis that included 18 studies and
40,280 patients conﬁrmed that staged PCI was consistently asso-
ciated with lower mortality.43 In a subanalysis of the HORIZONS-
AMI trial (harmonizing outcomes with revascularization and
stents in acute myocardial infarction), 688 patients who underwent
PCI of culprit and nonculprit vessel were categorized into single PCI
strategy vs. staged PCI: 1-year mortality (9.2% vs. 2.3%, p < 0.0001),
cardiac mortality (6.2% vs. 2.0%, p ¼ 0.005), and deﬁnite/probable
stent thrombosis (5.7% vs. 2.3%, p ¼ 0.02) were all in favor of staged
PCI.44
Several randomized controlled trials have advanced our un-
derstanding of optimal revascularization strategies in STEMI
(Table 4). Politi et al, in a study that included 263 patients,
showed that IRA-only PCI was associated with a higher rate of
MACE (death, reinfarction, rehospitalization for ACS, and repeat
coronary revascularization) during a mean follow-up of 2.5 years
compared with either staged PCI or simultaneous treatment of the
non-IRA (50.0% vs. 20.0% vs. 23.1%, p<0.001).3 The PreventiveTable 4
Randomized trials comparing IRA-only PCI vs. complete revascularization in stable patie
Study Number of
patients
Primary composite endpoint
Politi et al (2010)3 263 Cardiac or noncardiac death, in-hospital
for acute coronary syndrome, and repeat
mean follow-up.
PRAMI (2013)7 465 Death from cardiac causes, nonfatal my
at 23 months mean follow-up.
CvLPRIT (2015)5 296 All-cause death, recurrent myocardial in
driven revascularization within 12 mon
PRAGUE-13 (2015)46 214 All-cause mortality, nonfatal myocardia
median follow-up.
DANAMI-3-PRIMULTI (2015)4 627 All-cause mortality, non-fatal reinfarctio
revascularization of lesions in non-infar
enrolled patient had been followed up f
Compare-Acute (2017)6 885 Death from any cause, nonfatal myocard
cerebrovascular events at 12 months.
IRA, infarct-related artery; PCI, percutaneous coronary intervention; STEMI, ST-segmen
revascularization, CR, simultaneous treatment of non-infarct-related artery, HR, hazardAngioplasty in Acute Myocardial Infarction (PRAMI) trial ran-
domized 465 patients to IRA-only PCI (no preventive PCI) or IRA
and non-IRA PCI too (preventive PCI). Patients in the preventive
group had a lower rate of MACE (death from cardiac causes,
nonfatal myocardial infarction, or refractory angina) than those in
the no-preventive PCI group (21 vs. 53 cases, HR in the preventive
PCI group, 0.35 [0.21-0.58] 95% CI, p<0.001). However, there was
no statistically signiﬁcant difference in cardiac mortality between
the two groups (4 vs. 10 cases, HR 0.34 [0.1-1.08] 95% CI,
p ¼ 0.07).7 In the Complete versus Lesion-only Primary PCI trial
(CvLPRIT), investigators compared the outcomes of patients with
STEMI who had a complete revascularization during their hospital
stay (complete revascularization could be performed during the
index procedure or before hospital discharge) with patients who
had PCI only to the infarct-related artery. The primary endpoint
(all-cause death, recurrent MI, heart failure, and ischemia-driven
revascularization within 12 months) was signiﬁcantly lower
among patients who underwent complete revascularization
(10.0% vs. 21.2%, HR 0.45 [0.24-0.84] 95% CI, p ¼ 0.009). All-cause
mortality was numerically lower in the complete revasculariza-
tion group (2.7% vs. 6.9%, HR 0.38 [0.12-1.2] 95% CI, p ¼ 0.09).5 The
Complete revascularization versus treatment of the culprit lesion
only in patients with ST-segment elevation myocardial infarction
and multivessel disease (DANAMI-3ePRIMULTI) evaluated the
concept of complete revascularization not by using angiographic
criteria (percent stenosis) for non-IRA revascularization, but by a
functional test (FFR). Complete revascularization took place before
hospital discharge. The rate of the primary composite endpoint of
all-cause mortality, nonfatal reinfarction, and ischemia-drivennts with STEMI and multivessel disease
Results
death, re-infarction, re-hospitalization
coronary revascularization at 2.5 years
50% COR vs. 20% SR vs. 23.1% CR group,
p<0.001.
ocardial infarction, or refractory angina 9% in preventive PCI group vs. 23% in
non-preventive PCI group, p<0.001.
farction, heart failure, and ischemia-
ths.
10.0% in the complete revascularization
group vs. 21.2%, p<0.009, in the IRA-
only revascularization group.
l infarction, and stroke at 38 months 16.0% in complete revascularization
group vs. 13.9% in culprit lesion-only
PCI group, HR ¼ 1.35; 95% CI, 0.66-2.74.
n, and ischemia-driven
ct-related arteries when the last
or 1 year.
13% in patients who had complete
revascularization vs. 22% in patients
who had PCI of the IRA only, p< 0.004.
ial infarction, revascularization, and 8% in IRA-only PCI group vs. 21% in
complete revascularization group,
p<0.001.
t elevation myocardial infarction, COR, culprit vessel angioplasty-only; SR, staged
ratio; CI, conﬁdence interval.
Table 5
Guidelines for patients with STEMI and multivessel coronary artery disease without cardiogenic shock
Guidelines Recommendations Class Level of evidence
The 2015 ACC/AHA/SCAI
focused update on primary
PCI for patients with STEMI45
PCI of a noninfarct artery may be considered in selected patients with
STEMI and multivessel disease who are hemodynamically stable, either
at the time of primary PCI or as a planned staged procedure.
IIb B-R
ESC/EACS on myocardial
revascularization (2018)22
Routine revascularization of non-IRA lesions should be considered in
STEMI patients with multivessel disease before hospital discharge.
IIa A
ACC/AHA/SCAI, American College of Cardiology/American Heart Association/Society Cardiovascular Angiography Interventions; PCI, percutaneous coronary intervention;
STEMI, ST-segment elevation myocardial infarction; ESC/EACS, European Society of Cardiology/European Association of Cardiothoracic Surgery; non-IRA, non-infarct-related
artery.
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enrolled patient had been followed up for 1 year was signiﬁcantly
lower in the complete FFR-guided revascularization group (13% vs.
22%, HR 0.56, [0.38e0.83] 95% CI, p ¼ 0.004), driven by fewer
repeat revascularizations.4 In the Comparison Between FFR
Guided Revascularization Versus Conventional Strategy in Acute
STEMI Patients With Multivessel disease study (Compare-Acute),
the most current and largest randomized controlled trial in this
area to date, investigators evaluated the outcomes of FFR-guided
complete revascularization in patients with STEMI. The primary
composite endpoint of death from any cause, nonfatal MI, revas-
cularization, and cerebrovascular events at 12 months occurred in
8% of patients who had FFR-guided complete revascularization
and in 21% of patients who underwent IRA only PCI (HR 0.35,
[0.22 to 0.55] 95% CI, p<0.001).6
Interpretation of the above study ﬁndings should consider dif-
ferences in study design: in two studies (PRAMI and Compare-
Acute) non-IRA PCI took place during the index procedure, in one
(DANAMI3ePRIMULTI) during admission, in one (CvLPRIT) either
during index procedure or during hospital stay, while in the study
by Politi et al, patients were randomized to three different groups
(IRA PCI only, staged PCI, or repeat coronary revascularization).
Furthermore, two trials (DANAMI-3ePRIMULTI and Compare-
Acute) used FFR for guiding complete revascularization instead of
only using angiography.
In conclusion, current data favor complete revascularization
before hospital discharge; however, the optimal timing (during the
index procedure or later during the same hospitalization) and
whether revascularization should be guided by functional assess-
ment remain unclear. Importantly, none of the previously
mentioned studies showed lower mortality with non-IRA PCI. The
2015 ACC/AHA/SCAI focused update on primary PCI for patients
with STEMI recommends non-IRA PCI in selected hemodynamically
stable patients either during primary PCI or as a planned staged
procedure (class IIb, level of evidence B-R).45 The 2018 European
guidelines on myocardial revascularization suggest that “routine
revascularization of non-IRA lesions should be considered in STEMI
patients with multivessel disease before hospital discharge” (class
IIa, level of evidence A)22 (Table 5).4. Conclusion
Patients with cardiogenic shock in the setting of ACS should
undergo culprit-only coronary revascularization. Use of mechanical
circulatory support in such patients is increasing despite lack of
randomized controlled trials supporting their safety and efﬁcacy in
this setting. Multivessel revascularization during index admission
is reasonable and supported by several randomized controlled tri-
als particularly when guided by FFR, although it does not reduce
mortality. The optimal timing for achieving complete revasculari-
zation and the optimal strategy for evaluating the nonculprit le-
sions are still being debated.Disclosures
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